These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28464765)

  • 1. Functional Chemical Groups that May Likely Become a Source for the Synthesis of Novel Central Nervous System (CNS) Acting Drugs.
    Saganuwan SA
    Cent Nerv Syst Agents Med Chem; 2017; 17(3):178-186. PubMed ID: 28464765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piroxicam: Source for Synthesis of Central Nervous System (CNS) Acting Drugs.
    Saganuwan SA
    Cent Nerv Syst Agents Med Chem; 2017; 17(2):135-140. PubMed ID: 27439371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chirality of Central Nervous System (CNS) Acting Drugs: A Formidable Therapeutic Hurdle Against CNS Diseases.
    Saganuwan SA
    Cent Nerv Syst Agents Med Chem; 2019; 19(3):171-179. PubMed ID: 31232237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion of Benzimidazoles, Imidazothiazoles and Imidazoles into more Potent Central Nervous System Acting Drugs.
    Saganuwan SA
    Cent Nerv Syst Agents Med Chem; 2020; 20(1):3-12. PubMed ID: 31223095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of the use of transgenic animals in CNS drug discovery.
    Nestler EJ; Olivier B
    Curr Protoc Pharmacol; 2001 May; Chapter 5():Unit5.20. PubMed ID: 21965073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.
    Cole PE; Schwarz AJ; Schmidt ME
    Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What regulatory science can bring for CNS drug development.
    Gispen-de Wied C; Stoyanova-Beninska V
    Eur Neuropsychopharmacol; 2015 Jul; 25(7):967-8. PubMed ID: 26024929
    [No Abstract]   [Full Text] [Related]  

  • 8. In vivo Piroxicam Metabolites: Possible Source for Synthesis of Central Nervous System (CNS) Acting Depressants.
    Saganuwan SA
    Cent Nerv Syst Agents Med Chem; 2017; 17(3):172-177. PubMed ID: 27834137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Search for CNS active agents: synthesis of N,N'-bis-[potassium-alkyl/aryl carboxylate]-5-arylidene barbituric acids.
    Tiwari SS; Agarwal R; Satsangi RK
    Pol J Pharmacol Pharm; 1981; 33(1):115-20. PubMed ID: 7255277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-Bridged 5,6-bicyclic pyridines: Recent applications in central nervous system disorders.
    Delgado O; Delgado F; Vega JA; Trabanco AA
    Eur J Med Chem; 2015 Jun; 97():719-31. PubMed ID: 25542766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Start small and stay small. Minimizing attrition in the clinic with a focus on CNS therapeutics.
    Nienaber V
    Curr Top Med Chem; 2009; 9(18):1688-704. PubMed ID: 19929834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiophene Scaffold as Prospective Central Nervous System Agent: A Review.
    Deep A; Narasimhan B; Aggarwal S; Kaushik D; Sharma AK
    Cent Nerv Syst Agents Med Chem; 2016; 16(2):158-64. PubMed ID: 26844957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In this issue of Recent Patents on CNS Drug Discovery, focus is laid upon the potential development of new therapeutic drugs for neurological and affective disorders through targeting the endocannabinoid system. Introduction.
    Recent Pat CNS Drug Discov; 2012 Apr; 7(1):1-2. PubMed ID: 22384488
    [No Abstract]   [Full Text] [Related]  

  • 14. Thiazole: a promising heterocycle for the development of potent CNS active agents.
    Mishra CB; Kumari S; Tiwari M
    Eur J Med Chem; 2015 Mar; 92():1-34. PubMed ID: 25544146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Academic Drug Discovery in the Quest for New CNS Therapeutics.
    Yokley BH; Hartman M; Slusher BS
    ACS Chem Neurosci; 2017 Mar; 8(3):429-431. PubMed ID: 28195461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting neuronal function for CNS drug discovery.
    Hempel CM; Werley CA; Dempsey GT; Gerber DJ
    Drug Discov Today Technol; 2017 Mar; 23():17-25. PubMed ID: 28647082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of novel derivatives of 4-pyridine carboxylic acid hydrazide and their activity on central nervous system.
    Naeem S; Akhtar S; Mushtaq N; Kamil A; Zafar S; Anwar S; Arif M
    Pak J Pharm Sci; 2014 Sep; 27(5 Spec no):1401-8. PubMed ID: 25176234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Theoretical and practical applications of the intracerebroventricular route for CSF sampling and drug administration in CNS drug discovery research: a mini review.
    Kuo A; Smith MT
    J Neurosci Methods; 2014 Aug; 233():166-71. PubMed ID: 24937765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CNS Target Identification and Validation: Avoiding the Valley of Death or Naive Optimism?
    Hutson PH; Clark JA; Cross AJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():171-187. PubMed ID: 27575715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of PET ligand discovery to CNS drug development.
    Schmidt ME; Andrés JI
    Future Med Chem; 2017 Mar; 9(4):351-356. PubMed ID: 28263084
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.